Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/21/2013US20130309324 O-nitro compounds and pharmaceutical compositions including same
11/21/2013US20130309323 Compositions and methods for the treatment or prevention of chemoresistant neoplasia
11/21/2013US20130309322 Compositions for improving mental performance
11/21/2013US20130309316 Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use
11/21/2013US20130309313 Compositions and Methods for Increasing the Stability of Food Product Additives
11/21/2013US20130309311 Pellet formulation for the treatment of the intestinal tract
11/21/2013US20130309310 Injectable Nanoparticulate Olanzapine Formulations
11/21/2013US20130309307 Bilayer Pharmaceutical Tablet Comprising Telmisartan and a Diuretic and Preparation Thereof
11/21/2013US20130309306 Intrapulmonary benzodiazepine for the treatment and prevention of seizures
11/21/2013US20130309303 Opiod Agonist Formulations with Releasable And Sequestered Antagonist
11/21/2013US20130309302 Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
11/21/2013US20130309301 Salts of potassium atp channel openers and uses thereof
11/21/2013US20130309300 Fortification of nutritional products with olive extracts containing hydroxytyrosol and hydroxytyrosol fortified nutritional products
11/21/2013US20130309297 Long-lasting controlled-release liposome composition and method for producing same
11/21/2013US20130309292 Tobacco Alkaloid Releasing Chewing Gum
11/21/2013US20130309291 Confection composition
11/21/2013US20130309290 Gamma-tocopherol therapy for restenosis prevention
11/21/2013US20130309289 Drug Delivery From Stents
11/21/2013US20130309286 Glucan Compositions
11/21/2013US20130309266 Anti-regurgitation and/or anti-gastrooesophageal reflux composition, preparation and uses
11/21/2013US20130309253 Cancer treatment with endothelin receptor antagonists
11/21/2013US20130309252 Antagonists of grasp55 for use as a medicament
11/21/2013US20130309249 Materials and methods for the prophylactic treatment of a pre-malignant condition
11/21/2013US20130309244 Methods and compositions combining immunotherapy with monocyte activation
11/21/2013US20130309240 Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
11/21/2013US20130309238 Signal transduction pathway modulation
11/21/2013US20130309228 Pyrimidinediamine kinase inhibitors
11/21/2013US20130309225 Combination of cd37 antibodies with ice
11/21/2013US20130309224 Combination of cd37 antibodies with rituximab
11/21/2013US20130309220 Compositions for treating microbial infections
11/21/2013US20130309218 Process for producing aqueous solution containing fat-soluble substance
11/21/2013US20130309216 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
11/21/2013US20130309215 Pharmaceutical composition
11/21/2013US20130309211 Wnt1 for Treatment of Cardiovascular Disorders and Injuries
11/21/2013US20130309202 Methods for Improving Liver Function
11/21/2013US20130309201 Oligonucleotide chelate complex - polypeptide compositions and methods
11/21/2013US20130309200 Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
11/21/2013US20130309199 Novel Treatment of Multiple Sclerosis (MS)
11/21/2013US20130309198 Composition comprising at least to compounds which induces indolamine 2,3 - dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs
11/21/2013US20130309197 Inhibitors of cytochrome p450
11/21/2013US20130309196 Antiviral compounds
11/21/2013US20130309195 Antiviral compounds
11/21/2013US20130309191 Compounds for the treatment of clostridium difficile-associated disease
11/21/2013US20130309183 Skin anti-oxidant enhancing formulation and associated method
11/21/2013US20130309173 Methods and compositions for maintenance of a functional wound
11/21/2013DE102012009572A1 Agent, used to treat aquatic living beings against diseases caused by parasites, bacteria, fungi and viruses, comprises glycerol-formal or glycerol-formal containing compounds for formulating water-insoluble or poorly water-soluble drugs
11/21/2013DE102012002372B4 Konzentrat für eine Dialysierflüssigkeit und daraus hergestellte Dialysierflüssigkeit Concentrate for a dialysis fluid and derived dialysis fluid
11/20/2013EP2664672A1 Modified iRNA agents
11/20/2013EP2664671A1 Novel glycosyltransferase gene and use thereof
11/20/2013EP2664621A1 Antiviral agent
11/20/2013EP2664620A2 N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline form and processes
11/20/2013EP2664618A2 Chemokine receptor modulators
11/20/2013EP2664617A1 Method of making a 2,6-diaryl piperidine derivative
11/20/2013EP2664616A1 Hydantoin and thiohydantoin derivatives as antiviral drugs
11/20/2013EP2664615A1 Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
11/20/2013EP2664614A1 Palladium-copper catalysts for the homogeneous selective oxidation of thiol groups
11/20/2013EP2664606A1 An inhibitor of the production of advanced glycation end products
11/20/2013EP2664338A1 Suppressor for increase in blood gip level, suppressor for increase in blood insulin level, postprandial blood triglyceride level reducing agent, and suppressor for increase in blood glucose level
11/20/2013EP2664336A2 Regimens for intra-articular viscosupplementation
11/20/2013EP2664335A2 Regimens for intra-articular viscosupplementation
11/20/2013EP2664334A1 Regimens for intra-articular viscosupplementation
11/20/2013EP2664333A1 Polymeric iron chelating agent
11/20/2013EP2664332A1 Vaccine composition containing synthetic adjuvant
11/20/2013EP2664331A1 Novel Antibacterial Agents
11/20/2013EP2664330A1 Composition and medication containing Omega 3 fatty acids and a glucosaminoglucan
11/20/2013EP2664329A1 Ophthalmological vehicle system
11/20/2013EP2664328A1 Omega3 fatty acid compound preparation
11/20/2013EP2664327A1 Topical pharmaceutical compositions comprising terbinafide and urea
11/20/2013EP2664326A1 Combined therapy for cystic fibrosis
11/20/2013EP2664325A1 Methods for preventing or treating androgen mediated diseases
11/20/2013EP2664318A1 Antimicrobially active compositions based on zinc compound, glycerine monoalkyl ether and antioxidant
11/20/2013EP2663641A1 Mirna for treating diseases and conditions associated with neo-angiogenesis
11/20/2013EP2663566A1 5-([1,2,3]triazole-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives
11/20/2013EP2663565A2 Heteroaryl compounds and methods of use thereof
11/20/2013EP2663564A1 Imidazo [4, 5 -c]quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
11/20/2013EP2663562A1 Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
11/20/2013EP2663561A1 Novel heterocyclic derivatives and their use in the treatment of neurological disorders
11/20/2013EP2663560A1 Crystalline oxazine derivative and its use as bace inhibitor
11/20/2013EP2663559A1 Oxazine derivatives and their use in the treatment of neurological disorders
11/20/2013EP2663558A1 Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
11/20/2013EP2663557A1 Pyrimidine gyrase and topoisomerase iv inhibitors
11/20/2013EP2663555A2 Substituted benzoazepines as toll-like receptor modulators
11/20/2013EP2663553A2 Quinoline and isoquinoline compounds and methods of use thereof
11/20/2013EP2663550A2 Substituted benzoazepines as toll-like receptor modulators
11/20/2013EP2663549A1 Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
11/20/2013EP2663366A1 Amino acid composition and its use for treating intrauterine foetal growth restriction (iugr) or for parenteral nutrition of extremely pre-term infants
11/20/2013EP2663338A2 Oligosaccharide conjugates for targeting bacteria and uses related thereto
11/20/2013EP2663335A1 A composition for the regeneration of atrophic tissues
11/20/2013EP2663323A1 Methods targeting mir-128 for regulating cholesterol/lipid metabolism
11/20/2013EP2663315A1 Novel n-halamine acrylamide monomers and copolymers thereof for biocidal coatings
11/20/2013EP2663314A2 Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
11/20/2013EP2663313A1 Method for enhancing engraftment of haematopoetic stem cells
11/20/2013EP2663312A1 Irak inhibitors and uses thereof
11/20/2013EP2663311A2 Pyrimidinone derivatives as fatty acid synthase inhibitors
11/20/2013EP2663310A1 Oral dosage forms for modified release comprising tasocitinib
11/20/2013EP2663309A1 Processes for preparing isoquinolinones and solid forms of isoquinolinones
11/20/2013EP2663308A1 Bace-2 inhibitors for the treatment of metabolic disorders
11/20/2013EP2663307A1 Anti-angiogenic compound
11/20/2013EP2663306A1 Polymorphs of dexlansoprazole salts
11/20/2013EP2663305A1 Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
1 ... 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 ... 7860